BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BNTX BioNTech SE

盘后交易 02-17 16:07:51 EST

106.99

+1.12

+1.06%

盘后106.99

+0.000.00%

16:05 EST

最高107.56	最低105.41	成交量37.51万
今开106.00	昨收105.87	日振幅2.03%
总市值277.13亿	流通市值111.27亿	总股本2.59亿
成交额3,994万	换手率0.36%	流通股本1.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BNTX","market":"US","secType":"STK","nameCN":"BioNTech SE","latestPrice":106.99,"timestamp":1771362000000,"preClose":105.87,"halted":0,"volume":375111,"hourTrading":{"tag":"盘后","latestPrice":106.99,"preClose":106.99,"latestTime":"16:05 EST","volume":5517,"amount":590261.926635,"timestamp":1771362338373,"change":0,"changeRate":0,"amplitude":0.001028},"delay":0,"changeRate":0.010579011995843868,"floatShares":104000000,"shares":259027500,"eps":-2.797636,"marketStatus":"盘后交易","change":1.12,"latestTime":"02-17 16:07:51 EST","open":106,"high":107.56,"low":105.41,"amount":39943036.890305996,"amplitude":0.020308,"askPrice":107.9,"askSize":26,"bidPrice":107.04,"bidSize":73,"shortable":3,"etf":0,"ttmEps":-2.797636,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1771376400000},"marketStatusCode":4,"adr":0,"adrRate":1,"listingDate":1570680000000,"exchange":"NASDAQ","adjPreClose":105.87,"preHourTrading":{"tag":"盘前","latestPrice":106.1,"preClose":105.87,"latestTime":"09:27 EST","volume":966,"amount":102379.69005599999,"timestamp":1771338470107,"change":0.23,"changeRate":0.002172,"amplitude":0.010579},"postHourTrading":{"tag":"盘后","latestPrice":106.99,"preClose":106.99,"latestTime":"16:05 EST","volume":5517,"amount":590261.926635,"timestamp":1771362338373,"change":0,"changeRate":0,"amplitude":0.001028},"volumeRatio":0.642924,"impliedVol":0.4995,"impliedVolPercentile":0.757},"requestUrl":"/m/hq/s/BNTX/tweets","defaultTab":"tweets","newsList":[{"id":"1133871627","title":"Leerink Partners下调BioNTech SE评级至\"与市场持平\"，目标价微调至113美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133871627","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133871627?lang=zh_cn&edition=full","pubTime":"2026-02-02 20:08","pubTimestamp":1770034113,"startTime":"0","endTime":"0","summary":"投资机构Leerink Partners宣布将BioNTech SE（BNTX）的股票评级从\"跑赢大盘\"下调至\"与市场持平\"。与此同时，该机构将其目标股价从112.00美元小幅上调至113.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4568","BK4548","BK4139","BK4551","BNTX","BK4535"],"gpt_icon":0},{"id":"2605823476","title":"Biontech Se盘中异动 早盘大幅上涨5.00%报123.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605823476","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605823476?lang=zh_cn&edition=full","pubTime":"2026-01-22 23:11","pubTimestamp":1769094702,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日23时11分，Biontech Se股票出现波动，股价快速拉升5.00%。截至发稿，该股报123.90美元/股，成交量53.427万股，换手率0.21%，振幅3.97%。Biontech Se股票所在的生物技术行业中，整体涨幅为1.03%。Biontech Se公司简介：BioNTech是一家总部位于德国的生物技术公司，专注于开发癌症治疗药物，包括个体化免疫疗法，以及包括新冠病毒在内的传染病疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122231142a44a7757&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260122231142a44a7757&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BNTX","BK4585","BK4588","BK4535","BK4551","BK4568","BK4139"],"gpt_icon":0},{"id":"1126740215","title":"BioNTech预计未来五年将公布至少17项晚期临床试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1126740215","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126740215?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:08","pubTimestamp":1768219728,"startTime":"0","endTime":"0","summary":"BioNTech SE宣布，在接下来五年内，预计将从处于晚期开发阶段的临床试验中发布至少17项数据成果。在肿瘤治疗领域，该公司计划于2026年启动另外6项三期临床试验。若临床试验数据呈现积极结果，BioNTech有望在2030年前发展成为拥有多款肿瘤产品的企业。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4568","BNTX","BK4139","BK4548","BK4535","BK4551","BK4585"],"gpt_icon":0},{"id":"2602553921","title":"BioNTech、辉瑞大举进攻，PD-(L)1/VEGF双抗开始分化了","url":"https://stock-news.laohu8.com/highlight/detail?id=2602553921","media":"氨基观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602553921?lang=zh_cn&edition=full","pubTime":"2026-01-11 13:39","pubTimestamp":1768109940,"startTime":"0","endTime":"0","summary":"文｜氨基观察1月6日，美国Instil Bio宣布，其子公司Axion Bio决定终止与宜明昂科此前达成的合作协议，涉及PD-L1/VEGF双抗AXN-2510以及CTLA-4单抗AXN-27M。消息公布当日，Instil Bio股价暴跌53%，回落至交易前水平。尤其是随着PD-1+ADC的疗效被反复验证后，PD-1/VEGF双抗的联用正迅速铺开。/ 03 /分化开始AXN-2510的“退货”开启了PD-1/VEGF赛道的分化。截至目前，全球范围内PD-1/VEGF双抗的项目已超过40个，其中国内就有20余款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111134716a70cd852&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111134716a70cd852&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0210528500.USD","IE0002270589.USD","SG9999001176.USD","BK4568","SG9999002232.USD","BK4534","LU0868494617.USD","LU1057294990.SGD","LU1894683264.USD","LU0321505868.SGD","BK4599","LU0225284248.USD","LU1169590202.USD","PFE","SG9999001176.SGD","LU0053666078.USD","LU0122379950.USD","BK4588","IE00BLSP4452.SGD","SG9999013999.USD","LU0058720904.USD","IE00B19Z3581.USD","BK4533","LU0289739699.SGD","LU1023059063.AUD","BK4550","BNTX","LU0321505439.SGD","IE00B19Z3B42.SGD","BK4585","SG9999011175.SGD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU1169589451.USD","LU2487616109.SGD","LU0170899867.USD","BK4007","BK4107","LU1883839398.USD","LU1066053197.SGD","LU0985481810.HKD","BK4592","BK4023","LU1894683348.USD","LU0234572021.USD","LU0306806265.USD","IE00BLSP4239.USD","SG9999002224.SGD","BK4581","SG9999003800.SGD","LU0306807586.USD","LU1066051498.USD","LU0456855351.SGD","IE000M9KFDE8.USD","LU0225771236.USD"],"gpt_icon":1},{"id":"1196264094","title":"BioNTech完成对CureVac的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1196264094","media":"投资观察","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196264094?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:14","pubTimestamp":1766052856,"startTime":"0","endTime":"0","summary":"12月18日 - BioNTech SE宣布已完成对CureVac B.V.的收购，约86.75%的CureVac股份已被拍卖。CureVac将继续按照现有的业务流程运营，并将完成必要的分析，以确定未来的组织和投资组合结构。预计在2026年1月将强制收购剩余股份。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4588","BK4568","BNTX","BK4535","CVAC","BK4139","BK4548","BK4585"],"gpt_icon":0},{"id":"1103967501","title":"Biontech与施贵宝公布Pumitamig全球二期研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1103967501","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103967501?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:18","pubTimestamp":1765282713,"startTime":"0","endTime":"0","summary":"12月9日（路透社）- BioNTech SE与施贵宝首次公布PD-L1XVEGF-A双特异性抗体Pumitamig在晚期三阴性乳腺癌中的全球二期研究数据，显示出令人鼓舞的疗效。Pumitamig联合化疗实现了61.5%的确认客观反应率、71.8%的未确认客观反应率和92.3%的疾病控制率，与PD-L1表达水平无关。这些数据与先前在中国进行的1L TNBC I期/II期临床试验中报告的数据一致，并确认了关键III期ROSETTA BREAST-01试验的剂量选择。相关数据将于2025年圣安东尼奥乳腺癌研讨会上公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0237698245.USD","LU0061475181.USD","LU0985481810.HKD","LU0456855351.SGD","LU1093756168.USD","LU2125154778.USD","BK4534","LU1868836757.USD","IE00BJT1NW94.SGD","LU1718418525.SGD","BK4139","LU0267386448.USD","BK4007","LU2133065610.SGD","LU1670710661.SGD","LU1291159041.SGD","LU1430594728.SGD","LU2125154935.USD","LU1261432733.SGD","LU0306806265.USD","LU1868836914.USD","LU1989771016.USD","LU1323610961.USD","LU1585245621.USD","BK4548","BK4535","BK4585","LU1868836591.USD","LU2360032135.SGD","LU0096364046.USD","BK4551","LU0114720955.EUR","BMY","BK4588","LU1868837136.USD","LU0225284248.USD","LU0882574055.USD","LU1093756325.SGD","LU2242652126.USD","LU0321505439.SGD","IE00BJJMRZ35.SGD","LU0868494617.USD","IE0009355771.USD","LU1074936037.SGD","IE0002141913.USD","IE00BFXG1179.USD","LU1670711040.USD","LU1670710588.SGD","LU1032466523.USD","BK4559","LU1670711123.USD","IE00B2B36J28.USD","LU2242646821.SGD","LU1868837300.USD","BNTX","IE00BSNM7G36.USD","LU0306807586.USD","LU0321505868.SGD","BK4568","IE00BFTCPJ56.SGD","LU0225771236.USD","BK4581","LU1571399168.USD"],"gpt_icon":0},{"id":"1183793255","title":"异动解读 | BioNTech夜盘大涨6.22%，因肺癌药物GOTISTOBART获显著临床成果及FDA快速通道认证","url":"https://stock-news.laohu8.com/highlight/detail?id=1183793255","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183793255?lang=zh_cn&edition=full","pubTime":"2025-12-08 15:08","pubTimestamp":1765177718,"startTime":"0","endTime":"0","summary":"BioNTech SE（BNTX）今日夜盘大涨6.22%，市场反应积极。消息面上，BioNTech与OncoC4宣布，其选择性Treg调节剂GOTISTOBART在既往治疗的鳞状非小细胞肺癌患者中显示出临床上有意义的总体生存益处。该药物在降低死亡风险方面超过标准化疗超过一半，并已获得美国食品药品监督管理局（FDA）的快速通道认证。此外，在GOTISTOBART治疗组中，报告的≥3级治疗相关不良事件（AE）为19/45（42.2%），而多西他赛治疗组为20/41（48.8%）。这一积极数据增强了市场对BioNTech未来业绩的乐观预期，推动了股价上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BNTX"],"gpt_icon":0},{"id":"1100346533","title":"Biontech与OncoC4宣布肺癌药物显著改善总体生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1100346533","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100346533?lang=zh_cn&edition=full","pubTime":"2025-12-08 15:06","pubTimestamp":1765177604,"startTime":"0","endTime":"0","summary":"12月8日（路透社） - BioNTech表示，*BIONTECH与ONCOC4宣布选择性Treg调节剂GOTISTOBART在既往治疗的鳞状非小细胞肺癌患者中显示出临床上有意义的总体生存益处*GOTISTOBART在降低死亡风险方面超过标准化疗超过一半*GOTISTOBART已获得美国食品药品监督管理局（“FDA”）的快速通道认证*在GOTISTOBART治疗组中，报告的≥3级治疗相关不良事件（“AE”）为19/45（42.2%），而多西他赛治疗组为20/41（48.8%）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BNTX","BK4551","BK4588","BK4585","BK4139","BK4548","BK4535"],"gpt_icon":0},{"id":"1186165748","title":"美股疫苗股大跌，FDA 官员提及新冠疫苗与年轻男性心脏疾病有关联","url":"https://stock-news.laohu8.com/highlight/detail?id=1186165748","media":"老虎资讯综合","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186165748?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:25","pubTimestamp":1764635137,"startTime":"0","endTime":"0","summary":"在疫情期间，Prasad 因反对疫苗强制措施以及对新冠疫苗引发心肌炎风险的关注而在网上获得追随者。其他研究则发现，新冠感染导致心肌炎的风险高于接种疫苗。辉瑞和 BioNTech 共同研发了新冠疫苗 Comirnaty。两家公司均研发并销售新冠 mRNA 疫苗。这并非 Prasad 首次推动与 mRNA 新冠疫苗相关的变更。这位 FDA 官员还呼吁为疫苗临床试验设定不同的终点指标。","market":"us","thumbnail":"https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f5a0c542474fbfdd95db309645c9c3a7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"美股疫苗股大跌，FDA 官员提及新冠疫苗与年轻男性心脏疾病有关联","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DVAX","BNTX","MRNA","PFE"],"gpt_icon":1},{"id":"1152494916","title":"异动解读 | FDA提及儿童死亡与新冠疫苗关联，BioNTech盘中大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152494916","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152494916?lang=zh_cn&edition=full","pubTime":"2025-12-02 03:10","pubTimestamp":1764616233,"startTime":"0","endTime":"0","summary":"BioNTech SE (BNTX) 今日盘中大跌5.02%，引发了市场的广泛关注。消息面上，美国食品药品管理局（FDA）的一份备忘录提及儿童死亡与新冠疫苗的关联，导致疫苗股普遍下跌。BioNTech作为新冠疫苗的主要生产商之一，股价受到直接影响。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f5a0c542474fbfdd95db309645c9c3a7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BNTX"],"gpt_icon":0},{"id":"1199033044","title":"美股异动 | 疫苗股下跌，Moderna跌超6%！FDA提及儿童死亡与新冠疫苗关联","url":"https://stock-news.laohu8.com/highlight/detail?id=1199033044","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199033044?lang=zh_cn&edition=full","pubTime":"2025-12-01 23:26","pubTimestamp":1764602786,"startTime":"0","endTime":"0","summary":"12月1日，部分美股疫苗股盘中下跌，$Moderna(MRNA)$跌超6%，$诺瓦瓦克斯(NVAX)$跌近4%，$BioNTech(BNTX)$跌超3%。此前$美国食品(USFD)$药物管理局备忘录提及儿童死亡与新冠疫苗的关联。","market":"us","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f5a0c542474fbfdd95db309645c9c3a7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","BNTX","MRNA"],"gpt_icon":0},{"id":"1174710771","title":"BioNTech建议CureVac股东在2025年12月2日星期二东部时间下午6点前递交其股票","url":"https://stock-news.laohu8.com/highlight/detail?id=1174710771","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174710771?lang=zh_cn&edition=full","pubTime":"2025-11-26 20:48","pubTimestamp":1764161321,"startTime":"0","endTime":"0","summary":"11月26日 - BioNTech SE宣布，CureVac于2025年11月25日举行的特别股东大会上批准了与其公开收购（“要约”）有关的事项，涉及CureVac N.V.（NASDAQ：CVAC，简称“CureVac”）的所有已发行股票。CureVac的股东被建议在2025年12月2日星期二东部时间下午6点之前递交他们的股票。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BNTX","BK4585","BK4588","BK4139","BK4551","BK4548","CVAC","BK4568"],"gpt_icon":0},{"id":"1110169712","title":"Curevac重申其预期现金流可持续至2028年","url":"https://stock-news.laohu8.com/highlight/detail?id=1110169712","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110169712?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:24","pubTimestamp":1763987068,"startTime":"0","endTime":"0","summary":"2025年11月24日 - CureVac B.V.（CUREVAC NV）发布了第三季度的财报，第三季度收入为5410万欧元，超过IBES预估的334万欧元。同时，第三季度的息税前利润（EBIT）为3.102亿欧元。CureVac B.V.重申其预计的现金流将持续至2028年。此外，德国联邦反垄断局已批准BioNTech SE与CureVac的交易。在截至2025年9月30日的三个和九个月中，CureVac B.V.的净财务结果分别为260万欧元的亏损和220万欧元的利润。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVAC","BK4568","BK4535","BK4551","BK4585","BK4548","BK4588","BK4139","BNTX"],"gpt_icon":0},{"id":"1140001019","title":"辉瑞通过区块交易出售在BioNTech的剩余持股","url":"https://stock-news.laohu8.com/highlight/detail?id=1140001019","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140001019?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:38","pubTimestamp":1763573888,"startTime":"0","endTime":"0","summary":"11月13日 - 据彭博社报道知情人士消息：*辉瑞以每个美国存托凭证108至111.70美元的价格，通过隔夜区块交易出售在BioNTech的剩余持股*未注册发行的455万份存托凭证，以相较于周三收盘价高达3.3%的折扣进行出售 - 彭博社计算数据* 进一步公司报道：BNTX.OPFE.N*","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","SG9999002224.SGD","BK4585","IE00B19Z3581.USD","PFE","LU0321505439.SGD","BK4581","BK4592","BK4568","LU1066051498.USD","LU0306807586.USD","SG9999003800.SGD","SG9999013999.USD","IE00BLSP4239.USD","LU0868494617.USD","IE00BLSP4452.SGD","LU0985481810.HKD","SG9999002232.USD","LU0289739699.SGD","BK4007","LU1894683264.USD","BK4599","BK4551","LU0058720904.USD","LU0234572021.USD","LU1057294990.SGD","SG9999001176.USD","SG9999011175.SGD","BK4548","SGXZ57979304.SGD","BNTX","BK4535","LU0456855351.SGD","SG9999001176.SGD","LU1883839398.USD","LU0170899867.USD","LU1066053197.SGD","BK4534","BK4550","LU0225284248.USD","LU1894683348.USD","LU0122379950.USD","BK4533","BK4588","LU0306806265.USD","BK4139","IE00BBT3K403.USD","LU0321505868.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","LU0225771236.USD","IE000M9KFDE8.USD"],"gpt_icon":0},{"id":"1160719421","title":"异动解读 | BioNTech股价盘中大跌5.55%，辉瑞拟清仓所持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1160719421","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160719421?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:34","pubTimestamp":1763044446,"startTime":"0","endTime":"0","summary":"周四盘中，新冠疫苗生产商BioNTech SE股价大跌5.55%，引发市场关注。这一显著跌幅主要受到其合作伙伴辉瑞计划出售所持全部股份的消息影响。尽管辉瑞选择退出BioNTech的股权，但两家公司仍将基于BioNTech的专有mRNA技术继续合作开发COVID-19疫苗配方，并共享收益。随着疫情的结束，BioNTech已回归其最初的癌症治疗研发主线，并与百时美施贵宝达成了价值高达111亿美元的合作协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"34baabe47f7a1d7baf215626e698aaab","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BNTX"],"gpt_icon":0},{"id":"1168313532","title":"异动解读 | BioNTech股价盘前大跌5.10%，辉瑞拟清仓所持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1168313532","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168313532?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:26","pubTimestamp":1763044004,"startTime":"0","endTime":"0","summary":"周四盘前，新冠疫苗生产商BioNTech SE股价大跌5.10%，主要受到其合作伙伴辉瑞计划出售所持全部股份的消息影响。据知情人士透露，辉瑞正寻求通过隔夜大宗交易出售约455万份BioNTech的美国存托凭证，每股定价区间为108至111.70美元。辉瑞与BioNTech的合作始于2020年，双方共同开发的COVID-19疫苗在全球创下数百亿美元的收入。而BioNTech则回归其最初的癌症治疗研发主线，并与百时美施贵宝达成了价值高达111亿美元的合作协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"34baabe47f7a1d7baf215626e698aaab","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BNTX"],"gpt_icon":0},{"id":"2583569261","title":"新冠疫情时代的终结：辉瑞拟清仓BioNTech股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2583569261","media":"智通财经网","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583569261?lang=zh_cn&edition=full","pubTime":"2025-11-13 19:15","pubTimestamp":1763032552,"startTime":"0","endTime":"0","summary":"标志性疫苗合作落幕","market":"us","thumbnail":"https://static.tigerbbs.com/1d2a0f842b52974184983c9748f803fd","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1d2a0f842b52974184983c9748f803fd"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"34baabe47f7a1d7baf215626e698aaab","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368945.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BNTX","PFE"],"gpt_icon":1},{"id":"2582893262","title":"Biontech Se2025财年第三财季实现净利润-33.54百万美元，同比减少115.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582893262","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582893262?lang=zh_cn&edition=full","pubTime":"2025-11-09 00:01","pubTimestamp":1762617684,"startTime":"0","endTime":"0","summary":"11月9日，Biontech Se公布财报，公告显示公司2025财年第三财季净利润为-33.54百万美元，同比减少115.39%；其中营业收入为17.75亿美元，同比增加29.85%，每股基本收益为-0.14美元。从资产负债表来看，Biontech Se总负债33.65亿美元，其中短期债务62.75百万美元，资产负债比为7.46，流动比率为7.13。机构评级：截至2025年11月9日，当前有20家机构对Biontech Se目标价做出预测，其中目标均价为139.93美元，其中最低目标价为115.36美元，最高目标价为181.57美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251109000147a492f424&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251109000147a492f424&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4551","BK4588","BK4568","BNTX","BK4535","BK4139","BK4548","BK4585"],"gpt_icon":0},{"id":"2580732552","title":"德国药厂BioNtech(BNTX)第三财季收入同比升22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580732552","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580732552?lang=zh_cn&edition=full","pubTime":"2025-11-04 21:24","pubTimestamp":1762262656,"startTime":"0","endTime":"0","summary":"金吾财讯 | 以生产“复必泰”新冠疫苗知名的德国药厂BioNtech(BNTX)公布9月底止第三财季业绩，收入15.19亿欧元，按年升22%，优于市场预期的9.6亿欧元。由盈转亏，蚀2,870万欧元，对上财年同期赚1.98亿欧元，每股亏损0.12欧元。指引方面，公司上调今年全年收入，由原先介乎17亿至22亿欧元，上调至介乎26亿至28亿欧元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"294104","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FDAXmain","BK4548","BNTX","FDXMmain","BK4551","BK4588","BK4139","BK4535","BK4585","FDXSmain","BK4568"],"gpt_icon":0},{"id":"1143767555","title":"BioNTech第三季度运营收入为4689万欧元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143767555","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143767555?lang=zh_cn&edition=full","pubTime":"2025-11-03 19:59","pubTimestamp":1762171170,"startTime":"0","endTime":"0","summary":"11月3日 - BioNTech第三季度收入为15.189亿欧元，超过IBES预估的8.105亿欧元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX","BK4535","BK4548","BK4568","BK4551","BK4139","BK4585","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biontech.de","stockEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0298},{"period":"3month","weight":0.027},{"period":"6month","weight":-0.0674},{"period":"1year","weight":-0.1377},{"period":"ytd","weight":0.1121}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0595},{"period":"1year","weight":0.1181},{"period":"ytd","weight":-0.0002}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BioNTech SE成立于2008年6月2日。该公司结合了数十年的免疫学，尖端治疗平台以及各种患者分析和生物信息学工具的开创性研究，开发针对癌症和其他疾病的个体化免疫疗法。该公司利用强大的新治疗机制，利用各种生物学靶点，利用每位患者免疫系统的力量，解决每位患者潜在疾病的独特分子特征。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.014337},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.043382},{"month":3,"riseRate":0.666667,"avgChangeRate":0.099584},{"month":4,"riseRate":0.333333,"avgChangeRate":0.062444},{"month":5,"riseRate":0.666667,"avgChangeRate":0.046025},{"month":6,"riseRate":0.666667,"avgChangeRate":0.049136},{"month":7,"riseRate":1,"avgChangeRate":0.149272},{"month":8,"riseRate":0.5,"avgChangeRate":-0.051873},{"month":9,"riseRate":0.333333,"avgChangeRate":0.020492},{"month":10,"riseRate":0.666667,"avgChangeRate":0.023565},{"month":11,"riseRate":0.857143,"avgChangeRate":0.192937},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.033371}],"exchange":"NASDAQ","name":"BioNTech SE","nameEN":"BioNTech SE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioNTech SE,BNTX,BioNTech SE股票,BioNTech SE股票老虎,BioNTech SE股票老虎国际,BioNTech SE行情,BioNTech SE股票行情,BioNTech SE股价,BioNTech SE股市,BioNTech SE股票价格,BioNTech SE股票交易,BioNTech SE股票购买,BioNTech SE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}